.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Army
Novartis
Queensland Health
Chinese Patent Office
Moodys
Argus Health
Covington
AstraZeneca
Julphar

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,807,689

« Back to Dashboard

Which drugs does patent 7,807,689 protect, and when does it expire?


Patent 7,807,689 protects KAZANO, OSENI, and NESINA, and is included in three NDAs. There have been zero Paragraph IV challenges on Nesina and Kazano

This patent has forty-nine patent family members in thirty-one countries.

Summary for Patent: 7,807,689

Title:Dipeptidyl peptidase inhibitors
Abstract: The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
Inventor(s): Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/080,992
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-002Jan 25, 2013RXYesYes7,807,689► SubscribeYY METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-001Jan 25, 2013RXYesNo7,807,689► SubscribeYY METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-004Jan 25, 2013RXYesNo7,807,689► SubscribeYY METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-005Jan 25, 2013RXYesNo7,807,689► SubscribeYY METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-006Jan 25, 2013RXYesNo7,807,689► SubscribeYY METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,807,689

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,173,663Dipeptidyl peptidase inhibitors► Subscribe
8,288,539Dipeptidyl peptidase inhibitors► Subscribe
7,781,584Dipeptidyl peptidase inhibitors► Subscribe
7,906,523Dipeptidyl peptidase inhibitors► Subscribe
8,329,900Dipeptidyl peptidase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,807,689

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI363757► Subscribe
Taiwan201129553► Subscribe
TaiwanI344962► Subscribe
Taiwan200531695► Subscribe
Slovenia1586571► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Cipla
UBS
Chinese Patent Office
Merck
QuintilesIMS
Novartis
Baxter
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot